Tom Reeve Academic Surgical Clinic  ·  St Leonards

Site language
02 9438 2277
Thomas J. HughSpecialist Hepato-Biliary & General Surgeon
Site language

Research · Cholangiocarcinoma

Cholangiocarcinoma and bile duct cancer

Cholangiocarcinoma (bile duct cancer) prompts difficult questions about symptoms, surgery, and survival. Thomas J. Hugh's Sydney group has contributed pathology and proteomic research so GPs and patients understand intrahepatic cholangiocarcinoma alongside operable options.

Book a consultationAll conditions→

This page explains cholangiocarcinoma in plain language, alongside peer-reviewed work by Thomas J. Hugh and colleagues.

Plain-language patient guide→
/ 01Overview

What is cholangiocarcinoma?

Cholangiocarcinoma is cancer arising from bile duct lining cells. Intrahepatic cholangiocarcinoma starts inside the liver; perihilar and distal tumours sit near the hilum or pancreas. Bile duct cancer is often found late because early symptoms are subtle. MRI, CT, and ERCP with biopsy establish diagnosis and resectability.

Patients searching cholangiocarcinoma online need clear distinction from gallbladder cancer and hepatocellular carcinoma.

Tom Hugh works within HPB MDTs at major Sydney hospitals for staging and surgical planning.

/ 02Evidence

What cholangiocarcinoma symptoms appear first?

Cholangiocarcinoma symptoms may include painless jaundice, itchy skin, pale stools, dark urine, weight loss, or vague upper abdominal pain. Intrahepatic tumours can present with fewer biliary symptoms until mass effect occurs. New jaundice always needs urgent blood tests and imaging.

Symptom awareness helps GPs order the right scans before ascites or sepsis complicates care.

Scarlett, Samra, Hugh, and Smith (2006 Hepatology) explored proteomic profiles in malignant bile duct strictures, reflecting research into better diagnostics.

/ 03Evidence

What affects cholangiocarcinoma survival and prognosis?

Cholangiocarcinoma survival depends on tumour location, stage, margins after surgery, lymph nodes, and fitness. Complete resection offers the best prognosis for eligible patients. Unresectable disease relies on chemotherapy, stenting for jaundice, and clinical trials. Prognosis is individual; population averages cannot predict one person's course.

Andrici et al. (2016), including Hugh TJ, reported frequent BAP1 loss in intrahepatic cholangiocarcinoma, linking pathology to molecular behaviour.

Thomas J. Hugh explains surgical candidacy honestly when tumours involve major vessels or distant spread.

/ 04Evidence

How is bile duct cancer treated in specialist centres?

Treatment may combine major liver resection, bile duct excision, lymphadenectomy, and sometimes vascular reconstruction. Preoperative biliary drainage is used selectively. Stenting relieves jaundice before chemotherapy when surgery is not planned. Radiation roles vary; Hugh's group reported cholangiocarcinoma after external beam radiotherapy as rare secondary cases.

Kulkarni, Gill, Hugh, and Samra (2017) highlighted vigilance when new strictures appear after prior radiotherapy.

  • Resectable: MDT-approved hepatectomy and duct resection
  • Borderline: drainage, nutrition, neoadjuvant therapy trials
  • Unresectable: stents, systemic therapy, palliative support
/ 05Evidence

Where does Hugh's cholangiocarcinoma research focus?

Hugh's publications span diagnostic biomarkers, pathology subtyping, and complex HPB surgery outcomes. The goal is earlier correct diagnosis and better patient selection for aggressive resection in bile duct cancer.

Research complements Tom Hugh's operative practice so Sydney patients benefit from both bench and bedside experience.

/ 06Publications

Peer-reviewed publications by Thomas J. Hugh

The papers below are a selection of 66 papers from over 300 publications by Tom Hugh and collaborators, focused here on cholangiocarcinoma. Where a DOI or publisher link is available, it opens in a new tab so you can read the original research.
/ 07About the author

Who writes and operates from this evidence base?

Thomas J. Hugh is a specialist Upper GI and hepato-biliary surgeon and Chair of Surgery at the University of Sydney Northern Clinical School. He operates at Royal North Shore Hospital and North Shore Private, with consultations at the Tom Reeve Academic Surgical Clinic in St Leonards.

Outcomes across his practice are tracked through the DASO audit unit. That combination of published research and prospective audit is intended to keep advice grounded in measured results, not marketing claims.

Read more about Tom Hugh→
/ 08Common questions

No. They arise from different structures. Treatment and prognosis differ, though both are HPB cancers managed by similar teams.

Many intrahepatic tumours are resected with liver surgery when future liver volume and vascular involvement allow. MDT imaging review is essential.

Highly selected perihilar cases may be considered in transplant protocols at designated centres. Most patients are treated with resection or non-surgical therapy instead.

Jaundice or suspected bile duct cancer warrants urgent referral to an HPB surgeon or hepatobiliary MDT. Delay risks cholangitis and reduces treatment options.

/ 09Related reading